NASDAQ:AKCA - Akcea Therapeutics Stock Price, Forecast & News

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Akcea Therapeutics Inc (NASDAQ:AKCA) released its earnings results on Tuesday, November, 5th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.21. The company earned $20.62 million during the quarter, compared to the consensus estimate of $22.54 million. Akcea Therapeutics had a negative return on equity of 33.00% and a negative net margin of 50.71%. Akcea Therapeutics's quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.73) earnings per share. View Akcea Therapeutics' Earnings History.

Akcea Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Akcea Therapeutics.

Akcea Therapeutics will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 analysts have issued 12-month price objectives for Akcea Therapeutics' stock. Their forecasts range from $24.00 to $41.00. On average, they expect Akcea Therapeutics' stock price to reach $34.67 in the next year. This suggests a possible upside of 90.7% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.

Media coverage about AKCA stock has been trending negative recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Akcea Therapeutics earned a news impact score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the next few days. View News Stories for Akcea Therapeutics.

Akcea Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 4,100,000 shares, a decrease of 9.3% from the January 15th total of 4,520,000 shares. Based on an average daily volume of 272,100 shares, the days-to-cover ratio is currently 15.1 days. Approximately 47.7% of the company's shares are sold short. View Akcea Therapeutics' Current Options Chain.

Some companies that are related to Akcea Therapeutics include Ascendis Pharma A/S (ASND), The Medicines (MDCO), Horizon Therapeutics (HZNP), Amarin (AMRN), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), Evotec (EVTCY), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX) and Blueprint Medicines (BPMC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), Associated British Foods (ABF) and Chaarat Gold (CGH).

(AKCA) raised $125 million in an IPO on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

Akcea Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (11.50%), State Street Corp (0.71%), Point72 Asset Management L.P. (0.27%), Geode Capital Management LLC (0.27%), Charles Schwab Investment Management Inc. (0.16%) and Russell Investments Group Ltd. (0.12%). Company insiders that own Akcea Therapeutics stock include Ionis Pharmaceuticals Inc, Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Institutional Ownership Trends for Akcea Therapeutics.

AKCA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Rafferty Asset Management LLC, Geode Capital Management LLC, ProShare Advisors LLC and Motley Fool Asset Management LLC. Company insiders that have sold Akcea Therapeutics company stock in the last year include Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Insider Buying and Selling for Akcea Therapeutics.

AKCA stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Russell Investments Group Ltd., State Street Corp, Charles Schwab Investment Management Inc., Amia Capital LLP, Virtus ETF Advisers LLC and California Public Employees Retirement System. View Insider Buying and Selling for Akcea Therapeutics.

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKCA stock can currently be purchased for approximately $18.18.

Akcea Therapeutics has a market capitalization of $1.71 billion and generates $64.87 million in revenue each year. The company earns $-225,820,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.View Additional Information About Akcea Therapeutics.

The official website for Akcea Therapeutics is http://www.akceatx.com/.

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]